CEDAR KNOLLS, N.J.,
Jan. 15, 2020 /PRNewswire/ -- MYOS
RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a
bionutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
made from fertilized egg yolk that helps build lean muscle,
announced today that it will provide updates on its clinical
research including its clinically-backed nutrition product,
MYOS Canine Muscle Formula®, at the
North American Veterinary Meeting & Expo (VMX)
(https://navc.com/vmx/), Booth #2028,
January 19-22, 2020 in
Orlando, Florida.
The VMX Conference provides the animal health industry
with an opportunity to learn about innovative, state-of-the-art
products and services in addition to obtaining continuing education
(CE) certification in broad areas within Veterinary
Medicine.
Some of the key highlights that MYOS will provide updates on
include:
- The initiation of a randomized, double blind,
placebo-controlled clinical study to examine the impact of
Fortetropin on quality of life and mobility involving 40
geriatric dogs at Kansas State
University, under the direction of Professor Kenneth Harkin
DVM, DACVIM (SAIM).
- The initiation of a randomized, double blind,
placebo-controlled crossover clinical study at Animal Medical
Center to examine the impact of Fortetropin on serum myostatin
levels in dogs over the course of 24 hours, under the direction of
Leilani Alvarez, DVM, DACVSMR.
- The launch of MYOS Canine Muscle Formula Vet
Strength, an enhanced formulation of our highly rated
MYOS Canine Muscle Formula product that includes
branched chain amino acids ("BCAAs") for improved muscle growth and
recovery, which is available exclusively through our
nationwide network of Partner Veterinarians.
- The appointment of Albert Ahn,
DVM as a Strategic Adviser to guide the growth and development of
MYOS' rapidly expanding Animal Health Business. Dr. Ahn
brings with him over 25 years of leadership experience in the
Animal Health industry with leading companies such as Hill's Pet
Nutrition, Sumitomo and Merial.
"Since the launch of MYOS Canine Muscle Formula in
2018, it has become clear that this is a product that has
disruptive potential in the canine muscle health space," stated
Joseph Mannello, CEO of MYOS.
"This is evidenced not only by the incredible testimonials that we
continue to receive from dog owners across the country regularly,
but from positive results from clinical studies that we have
sponsored such as the Kansas State
University TPLO study wherein dogs who consumed Fortetropin
recovered faster from the surgery and had experienced less atrophy
of disuse in the leg that was operated on. As we continue to
grow our business, Animal Health remains one of our most exciting
areas of focus. We are committed to developing MYOS Canine
Muscle Formula into a brand that dog owners across the country
will not only recognize but utilize as an essential nutrition
product," added Mr. Mannello.
"It has become clear from reports in the veterinary literature
that improving the muscle health of dogs will result in reduced
morbidity and mortality. That being said, there are few
products that are commercially available to support muscle health
with the degree of scientific and clinical research behind them
that MYOS Canine Muscle Formula has. The product
has remarkable potential," commented Albert
Ahn, DVM, Strategic Adviser, MYOS RENS Technology, Inc.
The Northern American Veterinary Community (NAVC) Conference
/ VMX is one of the leading veterinary conferences in the
world. The event is expected to attract over17,000 veterinary
professionals from around the world in addition to over 700
corporate exhibitors. MYOS Canine Muscle
Formula® (Regular and Veterinarian
Strength) will be available at the conference in Booth
#2028. Please contact Andrea Libretti at
alibretti@myoscorp.com for additional product details.
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition
company that develops and markets products that improve muscle
health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass and reduce muscle atrophy.
MYOS believes Fortetropin has the potential to redefine existing
standards of physical health and wellness. For more information,
please visit www.myosrens.com.
About Myos Canine Muscle Formula®
Myos
Canine Muscle Formula (Regular and Veterinarian
Strength) is an advanced veterinary health supplement to
support muscle health in dogs, featuring Fortetropin as the
active ingredient. Fortetropin is made through a patented process
that maintains the vital nutrients of fertilized egg yolks to help
build more lean muscle and decrease muscle loss. For more
information, please visit www.myospet.com.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products,
including Qurr®, Yolked®,
MYOS Canine Muscle Formula®, Physician Muscle Health
Formula® and MYOS Enteral
Nutrition Formula™, the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects, the
ability to enter into new partnership opportunities and the success
of our existing partnerships, the ability to generate revenue and
cash flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-to-provide-exciting-updates-on-new-product-and-clinical-research-at-the-veterinary-meeting--expo-in-orlando-january-19-22-2020-300987081.html
SOURCE MYOS RENS Technology